TD Cowen and Goldman Sachs have raised their price targets for Royalty Pharma (RPRX), citing the company's unique position in the growing biopharma royalty market, portfolio diversification, and strong financial capacity for future deals.
Empress Royalty Corp. (CVE:EMPR) has transformed from loss to profitability, driving a 252% share price surge over three years. Recent momentum suggests the royalty financing model is gaining favor among investors seeking exposure to precious metals without operational risks.
Maxim Group raises its target on Gold Royalty Corp. (GROY) to $7, maintaining a Buy rating, citing recent acquisitions and a favorable gold price environment that are expected to drive the company toward profitability by 2026.
Buoyed by strong Phase 3 data for its lead drug zanidatamab, Zymeworks secures a major $250M royalty financing deal with Royalty Pharma, signaling a strategic shift towards a partnership and royalty-focused business model as it eyes a 2026 U.S. launch.
Goldman Sachs has raised its price target for Royalty Pharma to $51, following robust fourth-quarter results and guidance that outpaces analyst expectations. The firm highlights the company's strategic capital deployment and a long-term growth outlook exceeding 10%.
Summit Royalties has agreed to acquire a 1.0% net smelter return royalty on Newmont's Saddle North gold-copper deposit for C$5 million in shares, marking a strategic expansion into a major project under the world's leading gold producer.
Royalty Pharma (RPRX) reported a strong 2025, driven by double-digit growth and a pivotal move to internalize management. While guiding for moderated growth in 2026 amid headwinds, executives highlighted a record year for synthetic royalties and a robust pipeline of future catalysts.
Newmont Corporation has sold a 1% net smelter return royalty on its Saddle North gold-copper deposit to Summit Royalties Ltd., highlighting the growing role of alternative financing in major mining projects. The move provides Newmont with equity consideration while retaining operational control, reflecting a nuanced approach to capitalizing on its resource pipeline amid volatile commodity markets.
Silver Storm Mining has sold its capped production royalty on Nevada's Springer Mine for C$2.18 million, generating liquidity as it focuses capital on restarting its flagship La Parrilla Silver Mine Complex in Mexico by 2026.
Gold Royalty Corp (GROY) receives upgraded price targets and bullish ratings from major analysts, driven by revised precious metals forecasts and strategic acquisitions positioning the company for future growth.
Canadian miner i-80 Gold has locked in a comprehensive financing package worth up to half a billion dollars, anchored by a significant royalty deal with streaming giant Franco-Nevada. The capital injection is set to turbocharge development across its Nevada project portfolio and fund a sweeping recapitalization plan.
Bank of America Securities has lifted its price target for Franco-Nevada Corp. (FNV) to $280, citing revised metal price forecasts. The move follows the royalty company's major A$220 million investment to fast-track a key Australian gold project.
Franco-Nevada Corporation strengthens its foothold in Western Australia's gold sector with a major financing package for the Bullabulling project, signaling robust confidence in one of the country's premier development assets.
With a $20 million royalty deal from Chancery Royalty now sealed, KEFI Gold and Copper has completed the $340 million financing package for its flagship Ethiopian gold project. The company confirms field mobilization is underway, with a ground-breaking ceremony scheduled this month.
Colorado-based precious metals royalty firm Elemental Royalty will offer investors the option to receive quarterly dividends in Tether's gold-backed token XAUT, marking a significant corporate finance adoption of digital gold.
Gold Royalty Corp. (GROY) has bolstered its financial flexibility with an expanded $150 million credit facility, coinciding with record revenue growth from its portfolio of royalty-linked mines. The move has reignited investor interest, with shares posting strong returns, but questions remain about whether the current valuation fully captures the company's future potential.
Royalty Pharma announced stronger-than-expected 2025 results, hitting its five-year capital deployment goal early. Portfolio receipts surged 16% for the year, though the company forecasts a moderated growth rate for 2026 as it navigates upcoming patent expirations.
As the Canadian market recalibrates, investors are looking beyond tech for opportunities. We examine three penny stocks—GoldMining Inc., Steppe Gold Ltd., and Empress Royalty Corp.—that combine exploration potential, operational cash flow, and a unique royalty model to navigate current uncertainties.
Biotech firm Candel Therapeutics announces a dual $200 million financing strategy, combining a royalty deal with RTW Investments and a public stock offering, to fund the potential U.S. commercialization of its lead prostate cancer immunotherapy, CAN-2409.
XOMA Royalty Corp. (XOMA) delivered a fourth-quarter profit of $3.3 million, surpassing analyst forecasts, as its model of funding and collecting royalties on biotech innovations continues to gain traction.
